Tech war: Huawei to open-source AI chip toolkit to take on Nvidia’s proprietary platform


Huawei Technologies will open-source its Compute Architecture for Neural Networks (CANN) – the software toolkit used to develop applications on the firm’s Ascend AI processors – as the Shenzhen-based company steps up efforts to compete against Nvidia, days after Beijing raised concerns about its H20 chip’s security.
That move would help “speed up innovation from developers” and “make Ascend easier to use”, Huawei rotating chairman Eric Xu Zhijun said on Tuesday at the company’s developer conference in Beijing.

Huawei has already discussed with China’s leading artificial intelligence players, business partners, universities and research institutions how to build an open-source Ascend ecosystem, according to a statement from the company.

While the statement did not mention Nvidia’s proprietary Compute Unified Device Architecture (CUDA) toolkit, Huawei’s latest open-source initiative bolsters mainland China’s broad push for technology self-sufficiency, while creating an alternative platform that developers can use to build applications on domestic AI chips.

The open-source approach gives public access to a programme’s source code, allowing third-party software developers to modify or share its design, fix broken links or scale up its capabilities.

Image of Nvidia’s China-tailored H20 graphics processing units. Photo: Handout
Image of Nvidia’s China-tailored H20 graphics processing units. Photo: Handout
  • Related Posts

    China issues new safety rules for OpenClaw. Here are the dos and don’ts

    A unit of China’s Ministry of Industry and Information Technology (MIIT) has issued guidelines on best practices and prohibitions for adopting and using OpenClaw, the popular artificial intelligence agent that…

    Continue reading
    Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

    Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *